Updated on 8 October 2013
"Amaranth's Singapore activities have helped develop novel manufacturing processes for bioresorbable scaffolds, and significantly enhanced the minimally invasive cardiovascular interventions capabilities locally."
Amaranth Medical's Singapore facility will continue its advanced R&D activities and prepare for ramping up the production of its bioresorbable scaffold. Enrollment in the initial clinical study of FORTITUDE was recently completed, and preliminary results are expected to be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting taking place October 27-November 1, 2013 in San Francisco, CA.
"Among the recent advances in interventional cardiology, we believe that the development bioresorbable scaffolds is one of the most significant," said Fred M. Schwarzer, Managing Partner of Charter Life Sciences and Chairman of the Amaranth board of directors. "In our view, Amaranth Medical's FORTITUDE scaffold has significant inherent advantages over other bioresorbable scaffolds in development, and the entire investor group is committed to supporting Kamal and the Amaranth team in the development of this important technology to improve the lives of patients worldwide."